Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...


Scientific News

FARA funds research progress

In this section, you will find the most recent FA research publications, many of which are funded by FARA, as well as information on upcoming conferences and symposiums. You can search for articles by date using the archive box in the right hand column. To locate FARA Funded or Supported Research, click the hyperlink in the right hand column. You may also search for specific content using key words or phrases in the search button at the top right of your screen. Please be sure to visit other key research sections of our website for information on FARA’s Grant Program and the Treatment Pipeline.

Santhera starts European Phase III Study with its Lead Compound SNT-MC17 (idebenone) in Friedreich’s Ataxia

Santhera Pharmaceuticals AG (“Santhera”), a Swiss-based biopharmaceutical company focused on neuromuscular diseases, announced today that it has started a European Phase III clinical study with its lead product SNT-MC17 (idebenone) in Friedreich’s Ataxia (FRDA). The design of this study reflects the company’s discussions with EMEA which took place earlier this year and will evaluate both the cardiacand neurological benefits of SNT-MC17 (idebenone).

Santhera and the NIH Collaborate to Evaluate SNT-MC17 in FA

Santhera Pharmaceuticals AG (“Santhera”) of Switzerland announced today the start of a collaborative clinical trial with the US National Institutes of Neurological Disorders and Stroke (NINDS) at the National Institute of Health (NIH) to evaluate SNT-MC17 (idebenone) in patients affected by Friedreich’s ataxia (FRDA), a devastating life-threatening neuromuscular disease.

NINDS Recruiting Patients for Phase 2 Idebenone Study

The National Institute of Neurological Disorders and Stroke (NINDS) at NIH is recruting patients for a six month double-blind, placebo-controlled phase 2 clinical trial to determine the safety and efficacy of idebenone administered to patients with Friedreich's Ataxia. NINDS aims to enroll 48 patients composed of children (ages 9-11) and adolescents (ages 12-17) with FA divided evenly among 4 treatment arms (placebo, "low", "intermediate", and "high" dose idebenone).

Page 226 of 226




Archived in
  Scientific News



Tagged in
FARA Scientific News

Site Map     Privacy Policy      Service Terms      Contact      Charity Navigator